Literature DB >> 24381652

Improving blood and ECG monitoring among patients prescribed regular antipsychotic medications.

Parashar Pravin Ramanuj1.   

Abstract

Aims and methods It is now well established that antipsychotic medications are associated with adverse effects such as metabolic dysfunction, hyperprolactinaemia and cardiac arrhythmias. We completed an audit cycle between 2008 and 2010 to assess whether the implementation of a high-visibility prompt and an educational programme would improve monitoring rates among patients prescribed regular antipsychotics admitted to a 59-bedded psychiatric hospital in West Sussex. Results There was an improvement in monitoring rates for most audit standards. The greatest improvement was seen in measurement of random plasma glucose and cholesterol levels. Rates improved irrespective of the risk of metabolic dysfunction. However, prolactin measurement remained static and the ECG recording deteriorated. Clinical implications There appears to be a growing awareness of the need to screen for metabolic dysfunction among patients prescribed regular antipsychotic medication. A high-visibility prompt and educational programme helps to increase monitoring rates. However, more needs to be done to improve the mortality and morbidity rates among this patient subpopulation.

Entities:  

Keywords:  antipsychotic medication; metabolic dysfunction; monitoring

Year:  2013        PMID: 24381652      PMCID: PMC3822670     

Source DB:  PubMed          Journal:  Ment Health Fam Med        ISSN: 1756-834X


  14 in total

1.  Physical healthcare of people with severe mental illness: everybody's business!

Authors:  Kamini Vasudev; Brian V Martindale
Journal:  Ment Health Fam Med       Date:  2010-06

Review 2.  Metabolic monitoring for patients treated with antipsychotic medications.

Authors:  Tony A Cohn; Michael J Sernyak
Journal:  Can J Psychiatry       Date:  2006-07       Impact factor: 4.356

3.  Excess mortality of schizophrenia. A meta-analysis.

Authors:  S Brown
Journal:  Br J Psychiatry       Date:  1997-12       Impact factor: 9.319

4.  Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review.

Authors:  Marc De Hert; Vincent Schreurs; Kim Sweers; Dominique Van Eyck; Linda Hanssens; Sebastjan Sinko; Martien Wampers; Andre Scheen; Joseph Peuskens; Ruud van Winkel
Journal:  Schizophr Res       Date:  2008-03-04       Impact factor: 4.939

5.  A UK audit of screening for the metabolic side effects of antipsychotics in community patients.

Authors:  Thomas R E Barnes; Carol Paton; Mary-Rose Cavanagh; Elizabeth Hancock; David M Taylor
Journal:  Schizophr Bull       Date:  2007-05-04       Impact factor: 9.306

6.  Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia.

Authors:  A M Meaney; S Smith; O D Howes; M O'Brien; R M Murray; V O'Keane
Journal:  Br J Psychiatry       Date:  2004-06       Impact factor: 9.319

7.  Testing for diabetes in hospitalised patients prescribed antipsychotic drugs.

Authors:  David Taylor; Corina Young; Raadiyya Esop; Carol Paton; Rebecca Walwyn
Journal:  Br J Psychiatry       Date:  2004-08       Impact factor: 9.319

8.  Prevalence of diabetes mellitus among outpatients with severe mental disorders receiving atypical antipsychotic drugs.

Authors:  J Steven Lamberti; John F Crilly; Kumar Maharaj; David Olson; Karen Wiener; Stephen Dvorin; G Oana Costea; Margaret P Bushey; Marci B Dietz
Journal:  J Clin Psychiatry       Date:  2004-05       Impact factor: 4.384

9.  Prevalence of the metabolic syndrome among patients receiving clozapine.

Authors:  J Steven Lamberti; David Olson; John F Crilly; Telva Olivares; Geoffrey C Williams; Xin Tu; Wan Tang; Karen Wiener; Steven Dvorin; Marci B Dietz
Journal:  Am J Psychiatry       Date:  2006-07       Impact factor: 19.242

10.  A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients.

Authors:  Paul Mackin; David R Bishop; Helen M O Watkinson
Journal:  BMC Psychiatry       Date:  2007-06-25       Impact factor: 3.630

View more
  5 in total

1.  Cardiac Sudden Death in Psychiatric Patients.

Authors:  Hiroyuki Uchida; Takefumi Suzuki
Journal:  Can J Psychiatry       Date:  2015-05       Impact factor: 4.356

2.  Electrocardiographic monitoring for new prescriptions of quetiapine co-prescribed with acetylcholinesterase inhibitors or memantine from 2005 to 2009. A population study on community-dwelling older people in Italy.

Authors:  Claudio Bilotta; Carlotta Franchi; Alessandro Nobili; Paola Nicolini; Codjo Djignefa Djade; Mauro Tettamanti; Luca Pasina; Ida Fortino; Angela Bortolotti; Luca Merlino; Carlo Vergani
Journal:  Eur J Clin Pharmacol       Date:  2014-09-20       Impact factor: 2.953

3.  A Randomized Controlled Trial of a Patient-Centered Approach to Improve Screening for the Metabolic Side Effects of Antipsychotic Medications.

Authors:  Julie Kreyenbuhl; Lisa B Dixon; Clayton H Brown; Deborah R Medoff; Elizabeth A Klingaman; Li Juan Fang; Stephanie Tapscott; Mary Brighid Walsh
Journal:  Community Ment Health J       Date:  2016-04-09

4.  Utilization of the Behavior Change Wheel framework to develop a model to improve cardiometabolic screening for people with severe mental illness.

Authors:  Christina Mangurian; Grace C Niu; Dean Schillinger; John W Newcomer; James Dilley; Margaret A Handley
Journal:  Implement Sci       Date:  2017-11-14       Impact factor: 7.327

5.  The role of pharmacy in the management of cardiometabolic risk, metabolic syndrome and related diseases in severe mental illness: a mixed-methods systematic literature review.

Authors:  Dolly Sud; Eileen Laughton; Robyn McAskill; Eleanor Bradley; Ian Maidment
Journal:  Syst Rev       Date:  2021-03-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.